Effect of phospholipase A2inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study

Arthritis Research and Therapy

Volumn 6, Issue 3, 2004, Pages

  Thwin, Maung Maung ^a   Douni, Eleni ^b   Aidinis, Vassilis ^b   Kollias, George ^b   Kodama, Kyoko ^c   Sato, Kazuki ^c   Satish, Ramapatna L ^d   Mahendran, Ratha ^d   Gopalakrishnakone, Ponnampalam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^c FUKUOKA WOMEN'S UNIVERSITY   (Japan)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

peptide; rheumatoid arthritis; secretory phospholipase A2 inhibition; TNF transgenic mouse model; ultrastructural alterations

Indexed keywords

PEPTIDE; PHOSPHOLIPASE A; TUMOR NECROSIS FACTOR;

ANIMAL; ARTICLE; ARTICULAR CARTILAGE; C57BL MOUSE; CBA MOUSE; CELL LINE; CELL SURVIVAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; INFLAMMATION; MACROPHAGE; METHODOLOGY; MOUSE; OSTEOCHONDRITIS; PATHOLOGY; SYNOVITIS; TARSAL JOINT; TIME; TRANSGENIC MOUSE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANIMALS; CARTILAGE, ARTICULAR; CELL LINE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; INFLAMMATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; OSTEOCHONDRITIS; PEPTIDES; PHOSPHOLIPASES A; SYNOVITIS; TARSAL JOINTS; TIME; TUMOR NECROSIS FACTORS;

EID: 15044352795     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1179     Document Type: Article

References (41)

1. Nevalainen TJ, Haapamaki MM, Gronroos JM: Roles of secretory phospholipases A(2) in inflammatory diseases and trauma. Biochim Biophys Acta. 2000, 1488: 83-90. 10.1016/S1388-1981(00)00112-8. DOI: 10.1016/S1388-1981(00)00112-8
2. Lin MK, Farewell V, Vadas P, Bookman AA, Keystone EC, Pruzanski W: Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J Rheumatol. 1996, 23: 1162-1166.
3. Huwiler A, Staudt G, Kramer RM, Pfeilschifter J: Cross-talk between secretory phospholipase A2 and cytosolic phospholipase A2 in rat renal mesangial cells. Biochim Biophys Acta. 1997, 1348: 257-272. 10.1016/S0005-2760(97)00073-8. DOI: 10.1016/S0005-2760(97)00073-8
4. Jamal OS, Conaghan PG, Cunningham AM, Brooks PM, Munro VF, Scott KF: Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synovium. Ann Rheum Dis. 1998, 57: 550-558. DOI: 10.1136/ard.57.9.550
5. Vadas P, Pruzanski W, Kim J, Fox N: The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A2. Am J Pathol. 1989, 134: 807-811.
6. Bomalaski JS, Lawton P, Browning JL: Human extracellular recombinant phospholipase A2 induces an inflammatory response in rabbit joints. J Immunol. 1991, 146: 3904-3910.
7. Lin MK, Katz A, van den BH, Kennedy B, Stefanski E, Vadas P, Pruzanski W: Induction of secretory phospholipase A2 confirms the systemic inflammatory nature of adjuvant arthritis. Inflammation. 1998, 22: 161-173. 10.1023/A:1022336006109. DOI: 10.1023/A:1022336006109
8. Bidgood MJ, Jamal OS, Cunningham AM, Brooks PM, Scott KF: Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J Immunol. 2000, 165: 2790-2797. DOI: 10.4049/jimmunol.165.5.2790
9. Feldmann M: What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?. Int Arch Allergy Immunol. 1996, 111: 362-365. DOI: 10.1159/000237393
10. Akira S, Kishimoto T: IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev. 1992, 127: 25-50. DOI: 10.1111/j.1600-065X.1992.tb01407.x
11. Papadakis KA, Targan SR: Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000, 119: 1148-1157. DOI: 10.1053/gast.2000.18160
12. Triggiani M, Granata F, Oriente A, Gentile M, Petraroli A, Balestrieri B, Marone G: Secretory phospholipases A2 induce cytokine release from blood and synovial fluid monocytes. Eur J Immunol. 2002, 32: 67-76. 10.1002/1521-4141(200201)32:1<67::AID-IMMU67>3.0.CO;2-3. DOI: 10.1002/1521-4141(200201)32:1<67::AID-IMMU67>3.0.CO;2-3
13. Murakami M, Kuwata H, Amakasu Y, Shimbara S, Nakatani Y, Atsumi G, Kudo I: Prostaglandin E2 amplifies cytosolic phospholipase A2- and cyclooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2. J Biol Chem. 1997, 272: 19891-19897. 10.1074/jbc.272.32.19891. DOI: 10.1074/jbc.272.32.19891
14. Schrier DJ, Flory CM, Finkel M, Kuchera SL, Lesch ME, Jacobson PB: The effects of the phospholipase A2 inhibitor, manoalide, on cartilage degradation, stromelysin expression, and synovial fluid cell count induced by intraarticular injection of human recombinant interleukin-1 alpha in the rabbit. Arthritis Rheum. 1996, 39: 1292-1299. DOI: 10.1002/art.1780390805
15. Garcia-Pastor P, Randazzo A, Gomez-Paloma L, Alcaraz MJ, Paya M: Effects of petrosaspongiolide M, a novel phospholipase A2 inhibitor, on acute and chronic inflammation. J Pharmacol Exp Ther. 1999, 289: 166-172.
16. Miele L: Antiflammins. Bioactive peptides derived from uteroglobin. Ann N Y Acad Sci. 2000, 923: 128-140. DOI: 10.1111/j.1749-6632.2000.tb05524.x
17. Thwin MM, Gopalakrishnakone P, Kini RM, Armugam A, Jeyaseelan K: Recombinant antitoxic and antiinflammatory factor from the nonvenomous snake Python reticulatus: phospholipase A2 inhibition and venom neutralizing potential. Biochemistry. 2000, 39: 9604-9611. 10.1021/bi000395z. DOI: 10.1021/bi000395z
18. Thwin MM, Satish RL, Chan ST, Gopalakrishnakone P: Functional site of endogenous phospholipase A2 inhibitor from python serum. Eur J Biochem. 2002, 269: 719-727. 10.1046/j.0014-2956.2001.02711.x. DOI: 10.1046/j.0014-2956.2001.02711.x
19. Thwin MM, Ong WY, Fong CW, Sato K, Kodama K, Farooqui AA, Gopalakrishnakone P: Secretory phospholipase A2 activity in the normal and kainate injected rat brain, and inhibition by a peptide derived from python serum. Exp Brain Res. 2003, 150: 427-433.
20. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991, 10: 4025-4031.
21. Wooley PH: Collagen-induced arthritis in the mouse. Methods Enzymol. 1988, 162: 361-373. DOI: 10.1016/0076-6879(88)62091-X
22. Douni E, Sfikakis PP, Haralambous S, Fernandes P, Kollias G: Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther. 2004, 6: R65-R72. 10.1186/ar1028. DOI: 10.1186/ar1028
23. Arsenault AL, Lhotak S, Hunter WL, Banquerigo ML, Brahn E: Taxol (paclitaxel) involution of articular cartilage destruction in collagen induced arthritis: an ultrastructural demonstration of an increased superficial chondroprotective layer. J Rheumatol. 2000, 27: 582-588.
24. Henzgen S, Petrow PK, Thoss K, Brauer R: Degradation of articular cartilage during the progression of antigen-induced arthritis in mice. A scanning and transmission electron microscopic study. Exp Toxicol Pathol. 1996, 48: 255-263. DOI: 10.1016/S0940-2993(96)80012-1
25. Lapadula G, Nico B, Cantatore FP, La Canna R, Roncali L, Pipitone V: Early ultrastructural changes of articular cartilage and synovial membrane in experimental vitamin A-induced osteoarthritis. J Rheumatol. 1995, 22: 1913-1921.
26. Ghadially FN: Fine structure of the synovial joints. A text and atlas of the ultrastructure of normal and pathological articular tissues. 1983, London: Butterworth
27. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Turk B, Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G: Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 2002, 46: 785-792. 10.1002/art.10097. DOI: 10.1002/art.10097
28. Han Z, Chang L, Yamanishi Y, Karin M, Firestein GS: Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum. 2002, 46: 818-823. 10.1002/art.10104. DOI: 10.1002/art.10104
29. Snyder DW, Bach NJ, Dillard RD, Draheim SE, Carlson DG, Fox N, Roehm NW, Armstrong CT, Chang CH, Hartley LW, Johnson LM, Roman CR, Smith AC, Song M, Fleisch JH: Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. J Pharmacol Exp Ther. 1999, 288: 1117-1124.
30. Li P, Schwarz EM: The TNF-alpha transgenic mouse model of inflammatory arthritis. Springer Semin Immunopathol. 2003, 25: 19-33. 10.1007/s00281-003-0125-3. DOI: 10.1007/s00281-003-0125-3
31. Nevalainen TJ, Marki F, Kortesuo PT, Grutter MG, Di Marco S, Schmitz A: Synovial type (group II) phospholipase A2 in cartilage. J Rheumatol. 1993, 20: 325-330.
32. Pruzanski W, Bogoch E, Katz A, Wloch M, Stefanski E, Grouix B, Sakotic G, Vadas P: Induction of release of secretory nonpancreatic phospholipase A2 from human articular chondrocytes. J Rheumatol. 1995, 22: 2114-2119.
33. Miyaura C, Inada M, Matsumoto C, Ohshiba T, Uozumi N, Shimizu T, Ito A: An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation. J Exp Med. 2003, 197: 1303-1310. 10.1084/jem.20030015. DOI: 10.1084/jem.20030015
34. Kudo I, Murakami M: Diverse functional coupling of prostanoid biosynthetic enzymes in various cell types. Adv Exp Med Biol. 1999, 469: 29-35. DOI: 10.1007/978-1-4615-4793-8_5
35. Balsinde J, Balboa MA, Insel PA, Dennis EA: Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol. 1999, 39: 175-189. 10.1146/annurev.pharmtox.39.1.175. DOI: 10.1146/annurev.pharmtox.39.1.175
36. Vadas P: Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. J Lab Clin Med. 1984, 104: 873-881.
37. Mayer RJ, Marshall LA: New insights on mammalian phospholipase A2(s); comparison of arachidonoyl-selective and -nonselective enzymes. FASEB J. 1993, 7: 339-348.
38. Church WB, Inglis AS, Tseng A, Duell R, Lei PW, Bryant KJ, Scott KF: A novel approach to the design of inhibitors of human secreted phospholipase A2 based on native peptide inhibition. J Biol Chem. 2001, 276: 33156-33164. 10.1074/jbc.M101272200. DOI: 10.1074/jbc.M101272200
39. Lambeau G, Lazdunski M: Receptors for a growing family of secreted phospholipases A2. Trends Pharmacol Sci. 1999, 20: 162-170. 10.1016/S0165-6147(99)01300-0. DOI: 10.1016/S0165-6147(99)01300-0
40. Murakami M, Koduri RS, Enomoto A, Shimbara S, Seki M, Yoshihara K, Singer A, Valentin E, Ghomashchi F, Lambeau G, Gelb MH, Kudo I: Distinct arachidonate-releasing functions of mammalian secreted phospholipase A2s in human embryonic kidney 293 and rat mastocytoma RBL-2H3 cells through heparan sulfate shuttling and external plasma membrane mechanisms. J Biol Chem. 2001, 276: 10083-10096. 10.1074/jbc.M007877200. DOI: 10.1074/jbc.M007877200
41. Granata F, Balestrieri B, Petraroli A, Giannattasio G, Marone G, Triggiani M: Secretory phospholipases A2 as multivalent mediators of inflammatory and allergic disorders. Int Arch Allergy Immunol. 2003, 131: 153-163. 10.1159/000071481. DOI: 10.1159/000071481